Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816

• PubMed
Heerspink HJL, Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816)| false
• Search Google Scholar
• Export Citation

U.S. Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Aug. 26, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin

• PubMed
U.S. Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Aug. 26, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin)| false
• Search Google Scholar
• Export Citation

Perkovic V, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa1811744

• PubMed
Perkovic V, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa1811744)| false
• Search Google Scholar
• Export Citation

Packer M, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413–1424. doi: 10.1056/NEJMoa2022190

• PubMed
Packer M, EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413–1424. doi: 10.1056/NEJMoa2022190)| false
• Search Google Scholar
• Export Citation

Zannad F, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced Trial. Circulation [published online ahead of print Oct. 23, 2020]. doi: 10.1161/CIRCULATIONAHA.120.051685

• PubMed
Zannad F, Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced Trial. Circulation [published online ahead of print Oct. 23, 2020]. doi: 10.1161/CIRCULATIONAHA.120.051685)| false
• Search Google Scholar
• Export Citation

Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med [published online ahead of print Oct. 23, 2020]. doi: 10.1056/NEJMoa2025845; https://www.nejm.org/doi/full/10.1056/NEJMoa2025845

• PubMed
Bakris GL, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med [published online ahead of print Oct. 23, 2020]. doi: 10.1056/NEJMoa2025845; https://www.nejm.org/doi/full/10.1056/NEJMoa2025845)| false
• Search Google Scholar
• Export Citation

Agarwal R, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:1540–1550. doi: 10.1016/S0140-6736(19)32135-X

• PubMed
Agarwal R, Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:1540–1550. doi: 10.1016/S0140-6736(19)32135-X)| false
• Search Google Scholar
• Export Citation